Published in Neurology on February 01, 1981
Longitudinal study of serum antibody responses to bovine retinal S-antigen in endogenous granulomatous uveitis. Br J Ophthalmol (1983) 1.05
Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest (2013) 1.03
A longitudinal study of clinical and immunological findings in 52 patients with relapsing retinal vasculitis. Br J Ophthalmol (1988) 1.00
A prospective study of thymectomy and serum acetylcholine receptor antibodies in myasthenia gravis. Ann Surg (1982) 0.99
T helper cell recognition of muscle acetylcholine receptor in myasthenia gravis. Epitopes on the gamma and delta subunits. J Clin Invest (1993) 0.89
Epitopes on the beta subunit of human muscle acetylcholine receptor recognized by CD4+ cells of myasthenia gravis patients and healthy subjects. J Clin Invest (1994) 0.87
Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin Exp Immunol (1987) 0.87
Microscopic polyangiitis and myasthenia gravis: the battle of Occam and Hickam. Clin Rheumatol (2007) 0.87
B-cell-activating factor and autoimmune myasthenia gravis. Autoimmune Dis (2011) 0.82
Myasthenia gravis--current concepts. West J Med (1985) 0.78
[Correlation of acetylcholine receptor antibodies and clinical severity of myasthenia gravis in combined immunosuppressive therapy]. Eur Arch Psychiatry Neurol Sci (1984) 0.75
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A (1993) 15.04
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature (1995) 13.80
A report--chronic fatigue syndrome: guidelines for research. J R Soc Med (1991) 7.70
Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med (2001) 6.07
Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 5.68
Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 4.86
Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2000) 4.85
Detection of deletions spanning the Duchenne muscular dystrophy locus using a tightly linked DNA segment. Nature (1985) 4.62
Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature (1986) 4.13
Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA (1997) 4.00
Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J (2006) 3.92
Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts. Mol Psychiatry (2008) 3.68
SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. Am J Hum Genet (2000) 3.58
Apolipoprotein E and Alzheimer's disease. Annu Rev Neurosci (1996) 3.26
Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med (1998) 3.23
A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat Genet (1996) 2.98
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA (2001) 2.79
Linkage of Charcot-Marie-Tooth neuropathy type 1a to chromosome 17. Exp Neurol (1989) 2.58
Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci U S A (1995) 2.53
The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. JAMA (1997) 2.45
Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA (2001) 2.36
Risk prediction of prevalent diabetes in a Swiss population using a weighted genetic score--the CoLaus Study. Diabetologia (2009) 2.32
An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics (1992) 2.29
Drug-induced myopathies in man. Lancet (1978) 2.25
Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat Med (1996) 2.19
Understanding cell death in Parkinson's disease. Ann Neurol (1998) 2.16
Subthalamic deep brain stimulation and impulse control in Parkinson's disease. Eur J Neurol (2009) 2.13
ApoE genotype and survival from intracerebral haemorrhage. Lancet (1995) 2.07
Oxidative stress and the pathogenesis of Parkinson's disease. Neurology (1996) 2.05
Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci (2001) 2.04
Apolipoprotein E genotype: utility in clinical practice in Alzheimer's disease. J Am Geriatr Soc (1996) 2.03
An alpha-2-macroglobulin insertion-deletion polymorphism in Alzheimer disease. Nat Genet (1999) 2.01
Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. N Engl J Med (1999) 2.00
Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci (2000) 1.97
Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A (1994) 1.91
Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol (1996) 1.87
Linkage of Tunisian autosomal recessive Duchenne-like muscular dystrophy to the pericentromeric region of chromosome 13q. Nat Genet (1992) 1.87
Acute cerebral oedema induced by methotrexate. BMJ (1989) 1.79
Identification of novel genes in late-onset Alzheimer's disease. Exp Gerontol (2000) 1.74
Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci U S A (1994) 1.74
Clinical application of apolipoprotein E genotyping to Alzheimer's disease. Lancet (1994) 1.71
Neurodegeneration in the central nervous system of apoE-deficient mice. Exp Neurol (1995) 1.66
Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging (1996) 1.65
Novel polymorphism in the A4 region of the amyloid precursor protein gene in a patient without Alzheimer's disease. Neurology (1993) 1.64
Apolipoprotein E4 allele frequency, ischemic cerebrovascular disease, and Alzheimer's disease. Stroke (1993) 1.63
A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology (1998) 1.60
Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. N Engl J Med (1989) 1.59
Levodopa motor complications in Parkinson's disease. Trends Neurosci (2000) 1.58
Screening for mitochondrial cytopathies: the sub-anaerobic threshold exercise test (SATET). J Neurol Neurosurg Psychiatry (1989) 1.56
Isolation and localization of a slow troponin (TnT) gene on chromosome 19 by subtraction hybridization of a cDNA muscle library using myotonic dystrophy muscle cDNA. J Neurosci Res (1990) 1.55
Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest (1994) 1.54
Neurological presentations of hypothyroidism: the importance of slow relaxing reflexes. J R Soc Med (1995) 1.51
Glycine and neurodegenerative disease. Lancet (1991) 1.51
There is a pathologic relationship between ApoE-epsilon 4 and Alzheimer's disease. Arch Neurol (1995) 1.51
Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J (2008) 1.48
Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center. Ann Thorac Surg (1997) 1.48
Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease. Mov Disord (1993) 1.48
Localization of cloned unique DNA to three different regions of chromosome 19: screen for linkage probes for myotonic dystrophy. J Neurogenet (1985) 1.48
Linkage of a locus (CMT4A) for autosomal recessive Charcot-Marie-Tooth disease to chromosome 8q. Hum Mol Genet (1993) 1.47
The core assessment program for intracerebral transplantation. Mov Disord (1995) 1.47
Rapid brain autopsy. The Joseph and Kathleen Bryan Alzheimer's Disease Research Center experience. Arch Pathol Lab Med (1997) 1.46
Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol (1998) 1.45
No genetic effect of alpha1-antichymotrypsin in Alzheimer disease. Genomics (1996) 1.45
Risk of intracranial aneurysms in families with subarachnoid hemorrhage. Can J Neurol Sci (1995) 1.43
Carrier detection in Duchenne muscular dystrophy. N Engl J Med (1976) 1.42
Transgenic mouse model of early-onset DYT1 dystonia. Hum Mol Genet (2004) 1.42
Gold-induced neuroencephalopathy responding to dimercaprol. Lancet (1991) 1.42
Apoptosis in neurodegenerative diseases: the role of mitochondria. Biochim Biophys Acta (1999) 1.41
Apolipoprotein E in Creutzfeldt-Jacob disease. Lancet (1995) 1.41
Analysis of association at single nucleotide polymorphisms in the APOE region. Genomics (2000) 1.40
Histological surprise: callosal tuberculoma presenting as malignant glioma. J Neurol Neurosurg Psychiatry (1997) 1.40
Levodopa: why the controversy? Lancet (2002) 1.39
Progressive dementia and gait disorder in a 78 year old woman. J Neurol Neurosurg Psychiatry (2000) 1.39
Accelerated degradation of acetylcholine receptor from cultured rat myotubes with myasthenia gravis sera and globulins. Proc Natl Acad Sci U S A (1977) 1.39
Patent income. Science (1998) 1.38
Presenilin-1 polymorphism and Alzheimer's disease. Lancet (1996) 1.38
High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol (1997) 1.36
Human apolipoprotein E2, E3, and E4 isoform-specific transgenic mice: human-like pattern of glial and neuronal immunoreactivity in central nervous system not observed in wild-type mice. Neurobiol Dis (1996) 1.35
Localization of Charcot-Marie-Tooth disease type 1a (CMT1A) to chromosome 17p11.2. Genomics (1991) 1.35
Persistence of enteroviral RNA in chronic fatigue syndrome is associated with the abnormal production of equal amounts of positive and negative strands of enteroviral RNA. J Gen Virol (1990) 1.33
The genetic status of mothers of isolated cases of Duchenne muscular dystrophy. J Med Genet (1983) 1.32
Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins. J Virol (1992) 1.32
Localization of a gene (CMT2A) for autosomal dominant Charcot-Marie-Tooth disease type 2 to chromosome 1p and evidence of genetic heterogeneity. Genomics (1993) 1.29
Letter: Standardization of the E.S.R. Br Med J (1974) 1.28
X-linked neuropathy: gene localization with DNA probes. Ann Neurol (1986) 1.27
Clinical and genetic investigation in autosomal dominant limb-girdle muscular dystrophy. Neurology (1988) 1.26
Fine mapping of the chromosome 12 late-onset Alzheimer disease locus: potential genetic and phenotypic heterogeneity. Am J Hum Genet (2000) 1.26
Apolipoprotein E-epsilon 2 and Alzheimer's disease: genotype influences pathologic phenotype. Neurology (1997) 1.24
Hereditary motor and sensory neuropathy, X-linked: a half century follow-up. Neurology (1987) 1.23
Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol (1999) 1.22
Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol (1998) 1.22
Apolipoprotein E is localized to the cytoplasm of human cortical neurons: a light and electron microscopic study. J Neuropathol Exp Neurol (1994) 1.22
Apolipoprotein E and the CNS response to injury. J Cereb Blood Flow Metab (1998) 1.22
Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies. J Comp Neurol (1996) 1.21
Cellular localization of messenger RNA encoding amyloid-beta-protein in normal tissue and in Alzheimer disease. Alzheimer Dis Assoc Disord (1988) 1.18
Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann Neurol (2000) 1.18
Manganese intoxication and chronic liver failure. Ann Neurol (1994) 1.18